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The whole blood phagocytosis assay: 
a clinically relevant test of neutrophil function 
and dysfunction in community-acquired 
pneumonia
J. Reiné1*†, J. Rylance1,4†, D. M. Ferreira1, S. H. Pennington1, I. D. Welters2, R. Parker3 and B. Morton1,3,4
Abstract 
Objective: To refine and validate a neutrophil function assay with clinical relevance for patients with community-
acquired pneumonia (CAP).
Design: Two phase cross-sectional study to standardise and refine the assay in blood from healthy volunteers and 
test neutrophil phagocytic function in hospital patients with CAP.
Participants: Phase one: Healthy adult volunteers (n = 30). Phase two: Critical care patients with severe CAP (n = 16), 
ward-level patients with moderate CAP (n = 15) and respiratory outpatients (no acute disease, n = 15).
Results: Our full standard operating procedure for the assay is provided. Patients with severe CAP had significantly 
decreased neutrophil function compared to moderate severity disease (median phagocytic index 2.8 vs. 18.0, 
p = 0.014). Moderate severity pneumonia neutrophil function was significantly higher than control samples (median 
18.0 vs. 1.6, p = 0.015). There was no significant difference between critical care and control neutrophil function 
(median 2.8 vs. 1.6, p = 0.752).
Conclusions: Our whole blood neutrophil assay is simple, reproducible and clinically relevant. Changes in neutrophil 
function measured in this pneumonia cohort is in agreement with previous studies. The assay has potential to be 
used to identify individuals for clinical trials of immunomodulatory therapies, to risk-stratify patients with pneumonia, 
and to refine our understanding of ‘normal’ neutrophil function in infection.
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Introduction
Community-acquired pneumonia (CAP) is a major cause 
of morbidity and mortality. Disease results from both the 
bacterial infection, and the ensuing inflammatory host 
response, which, during early infection, is dominated by 
neutrophils. Neutrophil dysfunction is well recognised 
in patients with CAP and sepsis [1, 2]. Currently, there 
are no clinically validated laboratory tests of neutro-
phil function; this limits the development and testing of 
potential immunomodulatory therapies [3]. Personalised 
approaches to immunomodulatory drug administration 
could enhance positive outcomes and reduce the risk 
of potentially harmful adverse-effects [2]. We aimed to 
refine and validate a flow-cytometric whole blood assay 
of neutrophil phagocytic function using intraphagosomal 
reporter beads [4, 5]. Potential advantages of this assay 
are direct measurement of relevant biological activity, 
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minimal sample processing and the potential to become 
a ‘near-patient’ test with sample to result time of less than 
4 h.
Main text
Methods
We recruited healthy volunteers and hospital patients in 
a two-phase study. The North West-Haydock Research 
Ethics Service (UK) approved this study (15/NW/0869). 
In phase one, we refined our standard operating proce-
dure (SOP) using blood from healthy adult (> 18  years 
old) volunteers. In phase two, we recruited adult patients 
within 48  h of diagnosis of severe and moderate CAP 
(n = 16; defined by NICE guidelines, CG191: 2014 [6] 
who were admitted to critical and ward level care respec-
tively (n = 15). A control group of outpatients with 
chronic stable respiratory disease (no acute inflammatory 
disease, n = 15) were recruited for comparative purposes 
(July 2016–April 2017). Hospital patients were recruited 
from Aintree University Hospital and Royal Liverpool 
University Hospital, Liverpool, United Kingdom. Partici-
pants were excluded if diagnosed with an immunocom-
promising condition or therapy (including HIV infection, 
malignancy and long term (> 2  weeks) corticosteroid 
treatment), pregnant, requiring renal replacement ther-
apy, unable to provide informed consent.
Citrated blood samples were transported to the labo-
ratory and processed within 2 h of venepuncture. Final-
ised methods for the whole blood phagocytosis assay 
were refined based on previously published work [4, 5]. 
Samples were acquired using a BD LSR II flow cytom-
eter equipped with three lasers (405, 488, and 633  nm; 
Becton–Dickinson, USA), using compensation matri-
ces derived from commercial beads (Becton–Dickinson, 
USA). Data were acquired using FACS Diva software 
(version 6.1, BD Biosciences, USA) and analysed using 
FlowJo software (version 10, Tree Star, USA). A sequen-
tial gating strategy was used to identify the neutrophil 
according to light scatter and the expression of CD16 
(Additional file 1: Figure S1). Neutrophil oxidation ratio 
(OR) was calculated as the mean fluorescence intensity 
(MFI) of the reporter fluorophore (FITC) divided by the 
MFI of the calibrator fluorophore (Pacific Blue). To con-
firm the interaction of blood neutrophils and the intrap-
hagosomal reporter beads during the assay, illustrative 
confocal images and time-lapse video were also provided 
in Additional file 1: Figure S2, Video S1; Additional file 2.
Neutrophil phagocytic index (PI) was calculated as the 
number of neutrophils associated with reporter beads 
divided the total neutrophil number multiplied by the 
OR (Additional file 1: Figure S1). Statistical analysis was 
performed using Stata 13.1 for Mac (StataCorp LP, 2015); 
data were tested for normality using the Shapiro–Wilk 
test and analysed using parametric and non-parametric 
tests, as appropriate.
Results
We analysed whole blood samples from 16 patients with 
severe CAP admitted to critical care, 15 patients with 
moderate severity CAP admitted to hospital wards and 
15 patients with chronic, non-inflammatory and sta-
ble respiratory disease. Patient demographics, illness 
severity, microbiological status and outcome data were 
also recorded (Table  1). Median venepuncture to result 
(completed sample acquisition) time was 305 (IQR 261–
328) min, including median 91 (IQR 49–118) min trans-
port time between sampling and arrival in the laboratory. 
There were 45  min hands on time (i.e. pre-analytical 
interaction, reagent and sample preparation and loading, 
in-process interaction, post-analytical interaction and 
maintenance), per patient (sample batching promoted 
reductions).
Neutrophil phagocytic index (PI) was significantly 
higher in unstimulated blood samples taken from ward 
patients (moderate pneumonia) compared to criti-
cal care (severe pneumonia) patients [median 18.0 
(IQR = 3.0–48.7) vs. 2.8 (IQR = 2.8–9.3) p = 0.014] 
and outpatients [median 18.0 vs. 1.6 (IQR = 0.7–12.0), 
p = 0.015]. However, there was no significant difference 
between critical care and outpatients (Fig.  1a; median 
2.8 vs. 1.6, p = 0.752). For each group, PI value was sig-
nificantly increased after neutrophil stimulation with 
phorbol myristate acetate (PMA) and lipopolysaccha-
ride (LPS) (Fig. 1d–f). However, response to these posi-
tive controls was attenuated in critical care compared to 
ward patients. (Figure 1b, c) suggesting reduced maximal 
responses in the former group.
Discussion
We present a refined flow cytometry assay [5], clinically 
relevant method for measuring neutrophil function in 
blood taken from patients with CAP ex vivo. Our tech-
nique avoids pre-processing of blood, is simple to per-
form and reproducible. It directly measures phagocytic 
association with, and oxidation of neutrophils (repre-
sentative of host/pathogen interaction) and can deliver 
results within 4 h of venepuncture. This assay can detect 
attenuated phagocytic function in patients with severe 
compared to mild-moderate community acquired 
pneumonia.
Pneumonia is the most frequent source of sepsis 
requiring critical care admission and induces dispropor-
tionate rates of mortality and morbidity compared to 
other severe infections [7]. In light of increasing antimi-
crobial resistance, there is increased pressure to inves-
tigate potential immunomodulatory agents, such as 
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
     
    R
EV
ISE
D 
PR
OO
F
Journal : BMCTwo 13104 Dispatch : 26-3-2020 Pages : 5
Article No : 5034 ¨  LE ¨  TYPESET
MS Code :  þ   CP þ   DISK
Page 3 of 5Reiné et al. BMC Res Notes _#####################_ 
GM-CSF and interferon gamma [3], using a personalised 
approach to therapy [2]. To date, only indirect cell sur-
face markers of phagocyte function have been employed 
in clinical trials [8]. Previously described zymosan neu-
trophil assays require cell purification (removing the 
inflammatory milieu) and are time consuming [9]. Other, 
recently described, whole blood functional assays exist 
[10]; however, these have not been studied in the context 
of sepsis. Direct comparison of these functional assays 
would be useful. Our approach promotes direct measure-
ment of phagocytic function and will be used as the pri-
mary pharmacodynamic outcome measure for a planned 
first-in-human clinical trial with P4 peptide [5].
In summary, we present a simple, clinically relevant 
assay that can be used to measure neutrophil phago-
cytic function in patients who present clinically with 
community-acquired pneumonia. This approach has 
the potential to be applied in a wider clinical context to 
measure neutrophil function in inflammatory disease 
and potentially direct immunomodulatory therapies.
Limitations
Due to the relatively small cohort size, we were unable to 
study factors predictive of poor neutrophil function (e.g. 
microbiological status), or relationship to patient out-
comes. Future large-scale studies could assess these in 
cohorts suffering from pneumonia and undifferentiated 
sepsis disease states. Results could potentially be used 
to inform ‘normal-range’ neutrophil function and triage 
patient admission decisions (e.g. promote direct critical 
care admission) and/or direct targeted immunomodula-
tory therapies. Future investigations should seek to age-
match outpatient controls to mitigate for this potential 
confounding factor in our study.
Table 1 Clinical findings of ITU and ward patients in comparison to healthy control
ITU, severe sepsis patients; ward, sepsis patients; outpatient indicates healthy control; SOFA, sequential organ failure assessment score; CURB-65, pneumonia severity 
score based on confusion, urea nitrogen > 20 mg/dL, respiratory rate > 30 breaths/min, heart beat: Systolic BP < 90 mmHg or diastolic BP < or = 60 mmHg) and 
Age ≥ 65; ICU, intensive care unit; LOS; CPAP, continuous positive airway pressure; N/A, not applied
a Median (range)
b Median (25th–75th percentile)
ITU (n = 16) Ward (n = 15) Outpatient (n = 15)
Female 9 9 9
Agea 57 (38–68) 64 (38–80) 49 (43–63)
SOFAb 9 (4–12) 1 (0–3) N/A
CURB-65b 3 (3–4) 3 (1–4) N/A
Mortality (28 day) 2 0 0
Hospital LOS 18 (9–26) 6 (2–11) N/A
ICU LOS 10 (4-17) N/A N/A
Respiratory support Invasive ventilation = 11 Room air = 11 Room air = 15
Face mask CPAP = 3 Nasal specs = 4
Face mask high flow = 2
Microbiology No growth = 9 No growth = 15 N/A
S. pneumoniae = 3
E. coli = 1
Influenza = 1
Metapneumovirus = 2
Beta-lactam antibiotic (glycopeptide synthase 
inhibitor if penicillin allergic)
Benzylpenicillin = 4 Benzylpenicillin = 9 N/A
Amoxicillin = 2 Amoxicillin = 1
Tazocin = 9 Tazocin = 4
Teicoplanin = 1
Adjunct antibiotic Clarithromycin = 13 Clarithromycin = 11
Clindamycin = 1 Ciprofloxacin = 1
Gentamicin = 1
Metronidazole = 1
Antiviral Oseltamavir = 3 Oseltamivir = 1
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Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1310 4-020-05034 -0.
Additional file 1. Figures S1-S2, Video S1 caption, and standard operation 
procedure.
Additional file 2. Video S1.
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Fig. 1 Neutrophil phagocytic index in whole blood samples taken from patients with severe and mild/moderate severity community-acquired 
pneumonia (“ITU” and “ward” respectively), and respiratory outpatients with no acute inflammatory disease. Phagocytic index was calculated after 
45 min incubation. Neutrophils were identified according to the expression of CD16. Neutrophil oxidation ratio (OR) was calculated as the mean 
fluorescence intensity (MFI) of the reporter fluorophore (FITC) divided by the MFI of the calibrator fluorophore (Pacific Blue). Neutrophil phagocytic 
index (PI) was calculated as the number of neutrophils associated with reporter beads divided the total neutrophil number multiplied by the OR. 
Each dot represents data collected from a single volunteer. Samples were incubated at 37 °C, with shaking, in the presence of either a a vehicle 
control, b PMA or c LPS. Comparisons were made using Kruskall–Wallis (3 groups) and Mann–Whitney U (2 groups) tests, as appropriate
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